Relief reports u.s. collaboration partner announces journal of infectious diseases and treatment publishes positive aviptadil data in high comorbidity critical covid-19 patients w/ respiratory failure

Geneva, switzerland / accesswire / october 15, 2021 / relief therapeutics holding sa (six:rlf, otcqb:rlftf) (" relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its u.s. collaboration partner, nrx pharmaceuticals, inc. (nasdaq: nrxp) (" nrx "), has issued a press release announcing that the peer-reviewed journal of infectious diseases and treatment has published positive trial data from a prospective, open label, administratively controlled trial of aviptadil in high comorbidity patients suffering from critical covid-19 with respiratory failure. according to the press release, the study reported 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment at the houston methodist hospital (p
NRXP Ratings Summary
NRXP Quant Ranking